The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
Randomized, open-label, multicenter study to compare the efficacy and safety of combination
of iguratimod and danazol versus danazol for the treatment of adults with steroid-resistant/
relapse immune thrombocytopenia (ITP).
Phase:
Phase 2
Details
Lead Sponsor:
Peking University People's Hospital
Collaborators:
Beijing Friendship Hospital Beijing Hospital China-Japan Friendship Hospital First Affiliated Hospital of Chongqing Medical University Shanxi Bethune Hospital The First Affiliated Hospital of Zhengzhou University